is hers still selling compounded semaglutide Novo Nordisk Drops Hims & Hers: Inside the GLP-1 Crisis Hims & Hers Launches New

Eli Lilly CEO David Ricks announces details of the Medicare GLP-1 bridge program, offering weight loss medications like Fondeo and Zepbound for $50 per month to 20 million eligible Medicare Part D patients starting July 1.

Fella Health honors veterans with exclusive $100 off our Weight Loss programs

Recent Findings Newer generation GLP-1 based therapies have become more effective for the treatment of overweight and obesity, with data supporting tirzepatide as the most effective, followed by semaglutide and then liraglutide

Can frozen dinners labeled GLP-1 Friendly help?

Support appetite control with Calocurbs 100% natural, plant-based GLP-1 activator on Fullscript

FDA has agreed to the primary endpoint expected to be utilized in Phase 3 - Data from two Phase 2 studies of avexitide in people with PBH demonstrated highly statistically significant reductions in severe hypoglycemic events, an endpoint supported by the FDA - Avexitide was generally well tolerated, with a favorable safety profile replicated across five clinical trials in people with PBH - Management to host conference call and webcast today at